ATE406171T1 - Aplidine zur behandlung von multiplem myelom - Google Patents

Aplidine zur behandlung von multiplem myelom

Info

Publication number
ATE406171T1
ATE406171T1 AT04720081T AT04720081T ATE406171T1 AT E406171 T1 ATE406171 T1 AT E406171T1 AT 04720081 T AT04720081 T AT 04720081T AT 04720081 T AT04720081 T AT 04720081T AT E406171 T1 ATE406171 T1 AT E406171T1
Authority
AT
Austria
Prior art keywords
aplidine
multiple myeloma
treatment
medicament
manufacture
Prior art date
Application number
AT04720081T
Other languages
English (en)
Inventor
Joseph R Bertino
Daniel Medina
Glynn Thomas Faircloth
Constantine S Mitsiades
Kenneth Anderson
Nicholas Mitsiades
Original Assignee
Dana Farber Cancer Inst Inc
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Farber Cancer Inst Inc, Pharma Mar Sa filed Critical Dana Farber Cancer Inst Inc
Application granted granted Critical
Publication of ATE406171T1 publication Critical patent/ATE406171T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Production Of Liquid Hydrocarbon Mixture For Refining Petroleum (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT04720081T 2003-03-12 2004-03-12 Aplidine zur behandlung von multiplem myelom ATE406171T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45412503P 2003-03-12 2003-03-12
US52029303P 2003-11-14 2003-11-14

Publications (1)

Publication Number Publication Date
ATE406171T1 true ATE406171T1 (de) 2008-09-15

Family

ID=32994545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04720081T ATE406171T1 (de) 2003-03-12 2004-03-12 Aplidine zur behandlung von multiplem myelom

Country Status (20)

Country Link
US (1) US7381703B2 (de)
EP (1) EP1603584B1 (de)
JP (1) JP4584245B2 (de)
KR (1) KR101160320B1 (de)
AT (1) ATE406171T1 (de)
AU (1) AU2004218883B2 (de)
CA (1) CA2519789C (de)
CY (1) CY1108599T1 (de)
DE (1) DE602004016126D1 (de)
DK (1) DK1603584T3 (de)
ES (1) ES2312979T3 (de)
IL (1) IL170136A (de)
MX (1) MXPA05009742A (de)
NO (1) NO334264B1 (de)
NZ (1) NZ541611A (de)
PL (1) PL1603584T3 (de)
PT (1) PT1603584E (de)
RU (1) RU2335294C2 (de)
SI (1) SI1603584T1 (de)
WO (1) WO2004080477A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей
EP1942944A2 (de) * 2005-10-31 2008-07-16 Genentech, Inc. Makrozyklische depsipeptid-antikörper-wirkstoff-konjugate und entsprechende verfahren
PL2029155T3 (pl) * 2006-02-28 2016-09-30 Ulepszony sposób leczenia szpiczaka mnogiego
WO2008080956A1 (en) * 2006-12-29 2008-07-10 Pharma Mar, S.A. Prognostic molecular markers for the cancer therapy with aplidine
WO2009002553A1 (en) * 2007-06-25 2008-12-31 Prolexys Pharmaceuticals, Inc. Methods of treating multiple myeloma and resistant cancers
CA2703024A1 (en) * 2007-10-19 2009-04-23 Giuseppe Longo Sorbello Improved antitumoral treatments
KR20100131474A (ko) * 2008-03-07 2010-12-15 파르마 마르 에스.에이. 개선된 항암치료
NZ589270A (en) * 2008-05-16 2011-12-22 Pharma Mar Sa Multiple myeloma treatments
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4493796A (en) * 1980-09-12 1985-01-15 Board Of Trustees, Univ. Of Ill. Didemnins A, B, C, and derivatives thereof, as antiviral agents
DE3161556D1 (en) 1980-09-12 1984-01-05 Univ Illinois Novel antibiotics, derivatives thereof, processes for their extraction, and compositions containing them
US4950649A (en) * 1980-09-12 1990-08-21 University Of Illinois Didemnins and nordidemnins
IT1153974B (it) * 1982-09-23 1987-01-21 Erba Farmitalia Composizioni farmacologiche a base di cisplatino e metodo per il loro ottenimento
US4948791A (en) 1989-04-10 1990-08-14 The Board Of Trustees Of The University Of Illinois Novel Cytotoxic cyclic depsipeptides from the tunicate trididemnum solidum
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
DE4120327A1 (de) 1991-06-20 1992-12-24 Basf Ag Neue peptide, ihre herstellung und verwendung
US5462726A (en) * 1993-12-17 1995-10-31 Bristol-Myers Squibb Company Method of inhibiting side effects of solvents containing ricinoleic acid or castor oil or derivatives thereof employing a thromboxane A2 receptor antagonist and pharmaceutical compositions containing such solvents
CA2180260A1 (en) * 1993-12-29 1995-07-06 Dennis M. Brown Methods and compositions for the treatment of a host with a cellular proliferative disease
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
ES2102322B1 (es) 1995-07-13 1998-03-01 Pharma Mar Sa Procedimiento de preparacion de didemnina a.
ATE196844T1 (de) * 1996-05-22 2000-10-15 Protarga Inc Zusammensetzungen die konjugate von cis- docosahexaenoic-säure und taxotere enthalten
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
DK0918693T3 (da) 1996-07-03 2002-03-04 Paxton C G Ltd Beholdere
ATE321773T1 (de) 1996-10-24 2006-04-15 Univ Illinois Semisynthetisches verfahren zur herstellung von didemninanalogen
AU726146B2 (en) 1996-10-24 2000-11-02 Board Of Trustees Of The University Of Illinois, The Total synthesis of the amino hip analogue of didemnin A
US6034058A (en) * 1997-04-15 2000-03-07 Rinehart; Kenneth L. Semi-synthetic alanyl dilemnin analogs
US6030943A (en) * 1997-05-07 2000-02-29 Crumb; William J. Dehydrodidemnin B as an L-type calcium channel enhancer
GB9803448D0 (en) * 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
ES2235499T3 (es) 1998-07-30 2005-07-01 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Uso de derivados de propionil l-carnitina y de acetil l-carnitina en la preparacion de medicamentos con actividad anticancerigena.
US20010021380A1 (en) * 1999-04-19 2001-09-13 Pluenneke John D. Soluble tumor necrosis factor receptor treatment of medical disorders
JP2003500360A (ja) 1999-05-25 2003-01-07 ポイント セラピューティクス, インコーポレイテッド ボロプロリン化合物類を含む抗癌剤
US6890904B1 (en) * 1999-05-25 2005-05-10 Point Therapeutics, Inc. Anti-tumor agents
MXPA02004862A (es) * 1999-11-15 2003-01-28 Pharma Mar Sa Tratamiento de aplidina para canceres.
CA2405779A1 (en) 2000-04-07 2001-10-18 The Trustees Of The University Of Pennsylvania Tamandarin and didemnin analogs and methods of making and using them
US6509315B1 (en) * 2000-04-07 2003-01-21 The Trustees Of The University Of Pennsylvania Didemnin analogs and fragments and methods of making and using them
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
US7175849B2 (en) * 2000-10-05 2007-02-13 Immunex Corporation Nectin polypeptides
EP1330254B1 (de) * 2000-10-12 2005-07-06 Pharma Mar, S.A. BEHANDLUNG VON KREBSERKRANKUNGEN mit APLIDIN IN KOMBINATION MIT CARNITIN ODER ACETYLCARNITIN
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
US20040092583A1 (en) * 2001-01-02 2004-05-13 Elizabeth Shanahan-Prendergast Treatment for inhibiting neoplastic lesions
WO2003033013A1 (en) 2001-10-19 2003-04-24 Pharma Mar, S.A. Use of aplidine for the treatment of pancreatic cancer
RU2341283C2 (ru) 2003-03-12 2008-12-20 Фарма Мар, С.А. Усовершенствованное лечение опухолей

Also Published As

Publication number Publication date
AU2004218883B2 (en) 2009-10-01
EP1603584B1 (de) 2008-08-27
KR20060006779A (ko) 2006-01-19
DE602004016126D1 (de) 2008-10-09
MXPA05009742A (es) 2006-05-25
US20060172926A1 (en) 2006-08-03
JP4584245B2 (ja) 2010-11-17
US7381703B2 (en) 2008-06-03
WO2004080477A8 (en) 2004-11-11
EP1603584A1 (de) 2005-12-14
CA2519789C (en) 2012-07-03
CA2519789A1 (en) 2004-09-23
ES2312979T3 (es) 2009-03-01
NZ541611A (en) 2008-04-30
RU2005131578A (ru) 2006-01-27
US20070149445A9 (en) 2007-06-28
KR101160320B1 (ko) 2012-06-26
NO334264B1 (no) 2014-01-20
CY1108599T1 (el) 2014-04-09
IL170136A (en) 2014-04-30
DK1603584T3 (da) 2009-01-05
WO2004080477A1 (en) 2004-09-23
AU2004218883A1 (en) 2004-09-23
SI1603584T1 (sl) 2009-02-28
PL1603584T3 (pl) 2009-02-27
RU2335294C2 (ru) 2008-10-10
PT1603584E (pt) 2008-11-21
JP2006519828A (ja) 2006-08-31
NO20054668L (no) 2005-10-11

Similar Documents

Publication Publication Date Title
CY1108599T1 (el) Η απλιδινη στην αντιμετωπιση του πολλαπλου μυελωματος
ATE512163T1 (de) Verabreichung von mitteln zur behandlung von entzündungen
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
DE60328476D1 (de) Medizinisches ballonsystem zur behandlung von adipositas
DE602004020072D1 (de) 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen
ATE413385T1 (de) Zur behandlung von schmerzen geeignete therapeutische mittel
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
DE60113496D1 (de) Verwendung von Glycyrrhizin zur Behandlung von Mastitis.
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
ATE319439T1 (de) Mittel zur behandlung von erkrankungen des tracheo-bronchialtraktes, insbesondere der copd
DE60136477D1 (de) Retinoide zur behandlung von emphysem
ATE468849T1 (de) Idebenon zur behandlung von muskeldystrophien
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
RS50148B (sr) Upotreba docetaksela za lečenje hepatoćelijskog karcinoma
DE60213116D1 (de) Verwendung von carbinolen zur behandlung von neuropathischer funktionsstörung
ATE359808T1 (de) Verwendung von sarp-1 zur behandlung und/oder vorbeugung von scleroderma
ATE392212T1 (de) Verwendung eines proteasom-inhibitors zur behandlung fibrotischer erkrankungen
ATE536874T1 (de) Dreifache monoamin-wiederaufnahmehemmer zur behandlung von chronischen schmerzen
TNSN06147A1 (en) Use of cathepsin k inhibitors for treating of severe bone loss diseases
ATE291425T1 (de) R-eliprodil zur behandlung von glaucoma
ATE343387T1 (de) S-methyl-dihydro-ziprasidon zur behandlung von augenerkrankungen.
ATE373477T1 (de) Cci-779 zur behandlung von mantelzelllymphom
DE602005011029D1 (de) Therapeutisches mittel zur behandlung von plasmazellneoplasien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1603584

Country of ref document: EP